Artiva Biotherapeutics, Inc. (ARTV)
Nasdaq · Healthcare · Biotechnology
$7.13+4.39%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $349M
- 52-week range
- $2.71 – $14.53
- 52-week change
- +135.52%
- EPS (trailing)
- −$3.23
- Analyst rating
- 1.2 Strong buy
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$83.9M
- Diluted EPS
- −$3.43
- Free cash flow
- −$79.3M
From the company’s annual report on SEC EDGAR.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 115 employees · artivabio.com